Iterum Education Ab

Iterum Education Ab company information, Employees & Contact Information

Utveckla dig – oavsett befattning och var i karriären du befinner dig! Kompetensutveckling är en viktig investering för framtiden och för att du och din organisation ska utvecklas i era yrkesroller. Kompetens ger kraft och skapar trygghet och utveckling i arbetslivet i stort. Verksamheter som satsar på kompetensutveckling är mer lönsamma och attraktiva än andra. Iterum har lång erfarenhet av att ta fram utbildningar för kompetensutveckling inom lön, redovisning och arbetsmiljö. Vi har ett brett utbud av olika aktiviteter och kurser för att kunna tillgodose just ditt och din organisations behov, med allt från till exempel eKurser, kursdagar, temadagar och vår populära Lönecirkel. Välkommen att ta del av vårt utbud på iterum.se. Varmt välkommen att kontakta oss om du har frågor, vi vill gärna hjälpa dig och/eller din organisation att utvecklas åt rätt håll.
Looking for a particular Iterum Education Ab employee's phone or email?

Iterum Education Ab Questions

News

Two posters at IDWeek 2025: Iterum Therapeutics to present sulopenem data and host Learning Lounge Oct 21 - Stock Titan

Two posters at IDWeek 2025: Iterum Therapeutics to present sulopenem data and host Learning Lounge Oct 21 Stock Titan

Iterum Therapeutics Provides Business Update - Yahoo Finance

Iterum Therapeutics Provides Business Update Yahoo Finance

Iterum Launches UTI Drug, First Oral Penem Antibiotic Commercially Available in US - BioPharm International

Iterum Launches UTI Drug, First Oral Penem Antibiotic Commercially Available in US BioPharm International

Behind Iterum's 'dual-track' strategy to launch nation's first new uncomplicated UTI drug in 25 years - Fierce Pharma

Behind Iterum's 'dual-track' strategy to launch nation's first new uncomplicated UTI drug in 25 years Fierce Pharma

Iterum Therapeutics sees cash runway into 2026 - Yahoo Finance

Iterum Therapeutics sees cash runway into 2026 Yahoo Finance

Iterum Earnings Show $13M Cash as Revolutionary UTI Antibiotic ORLYNVAH Readies for Historic Launch - Stock Titan

Iterum Earnings Show $13M Cash as Revolutionary UTI Antibiotic ORLYNVAH Readies for Historic Launch Stock Titan

Iterum Therapeutics Reports Second Quarter 2025 Financial Results - Yahoo Finance

Iterum Therapeutics Reports Second Quarter 2025 Financial Results Yahoo Finance

Iterum opens PET recycling plant in Latvia - Recycling Today

Iterum opens PET recycling plant in Latvia Recycling Today

New Antibiotic ORLYNVAH Launches in US: Iterum Therapeutics Targets Multi-Drug Resistant Infections - Stock Titan

New Antibiotic ORLYNVAH Launches in US: Iterum Therapeutics Targets Multi-Drug Resistant Infections Stock Titan

FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment - Pharmaceutical Technology

FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment Pharmaceutical Technology

US FDA approves Iterum's treatment for urinary infection - Reuters

US FDA approves Iterum's treatment for urinary infection Reuters

Iterum Therapeutics Announces Partnership for Commercialization Services - Yahoo Finance

Iterum Therapeutics Announces Partnership for Commercialization Services Yahoo Finance

After prior rejection, Iterum nabs long-sought FDA nod for oral UTI drug Orlynvah - Fierce Pharma

After prior rejection, Iterum nabs long-sought FDA nod for oral UTI drug Orlynvah Fierce Pharma

Iterum Therapeutics Strengthens Leadership Team: New CCO to Drive Next-Gen Antibiotics Commercialization - Stock Titan

Iterum Therapeutics Strengthens Leadership Team: New CCO to Drive Next-Gen Antibiotics Commercialization Stock Titan

Iterum Therapeutics plc (NASDAQ:ITRM): When Will It Breakeven? - Yahoo Finance

Iterum Therapeutics plc (NASDAQ:ITRM): When Will It Breakeven? Yahoo Finance

First-Ever Oral Penem Antibiotic: Iterum's ORLYNVAH Launches to Combat Drug-Resistant UTIs in Women - Stock Titan

First-Ever Oral Penem Antibiotic: Iterum's ORLYNVAH Launches to Combat Drug-Resistant UTIs in Women Stock Titan

Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... - Yahoo Finance

Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... Yahoo Finance

Breakthrough UTI Drug ORLYNVAH Set for Q4 2025 Launch: First Oral Penem Antibiotic in US History - Stock Titan

Breakthrough UTI Drug ORLYNVAH Set for Q4 2025 Launch: First Oral Penem Antibiotic in US History Stock Titan

Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth - Yahoo Finance

Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth Yahoo Finance

Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance

Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ... Yahoo Finance

Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. - Yahoo Finance

Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. Yahoo Finance

Orlynvah From Iterum Therapeutics - Pharmacy Times

Orlynvah From Iterum Therapeutics Pharmacy Times

FDA concerned Iterum's urinary tract infection drug could cause antimicrobial resistance - Fierce Biotech

FDA concerned Iterum's urinary tract infection drug could cause antimicrobial resistance Fierce Biotech

Iterum brings first oral penem antibiotic to US market - pharmaphorum

Iterum brings first oral penem antibiotic to US market pharmaphorum

Iterum therapeutics (ITRM) director Dunne buys $10,854 in shares - Investing.com

Iterum therapeutics (ITRM) director Dunne buys $10,854 in shares Investing.com

Iterum Therapeutics Inks Partnership With EVERSANA For Commercialization Of ORLYNVAH In US - Nasdaq

Iterum Therapeutics Inks Partnership With EVERSANA For Commercialization Of ORLYNVAH In US Nasdaq

Iterum breaks UTI drug approval drought with FDA nod for Orlynvah - FirstWord Pharma

Iterum breaks UTI drug approval drought with FDA nod for Orlynvah FirstWord Pharma

Iterum Therapeutics Secures Critical $5M Funding: ORLYNVAH Drug Launch Plans Accelerate - Stock Titan

Iterum Therapeutics Secures Critical $5M Funding: ORLYNVAH Drug Launch Plans Accelerate Stock Titan

Iterum Therapeutics’ Earnings Call: Optimism Amid Challenges - TipRanks

Iterum Therapeutics’ Earnings Call: Optimism Amid Challenges TipRanks

Iterum Wins FDA Approval For Oral UTI Antibiotic, Seeks ‘Strategic Transaction’ for Asset - BioSpace

Iterum Wins FDA Approval For Oral UTI Antibiotic, Seeks ‘Strategic Transaction’ for Asset BioSpace

FDA Action Alert: Amgen, Camurus, Iterum and Lexicon - BioSpace

FDA Action Alert: Amgen, Camurus, Iterum and Lexicon BioSpace

Iterum Strengthens Launch Strategy: 30-Year Pharma Veteran Christine Coyne to Lead ORLYNVAH Commercialization - Stock Titan

Iterum Strengthens Launch Strategy: 30-Year Pharma Veteran Christine Coyne to Lead ORLYNVAH Commercialization Stock Titan

Iterum Gains 3-Year Extension on $20M Pfizer Payment, Strengthens ORLYNVAH Launch Strategy - Stock Titan

Iterum Gains 3-Year Extension on $20M Pfizer Payment, Strengthens ORLYNVAH Launch Strategy Stock Titan

Analysts Expect Breakeven For Iterum Therapeutics plc (NASDAQ:ITRM) Before Long - simplywall.st

Analysts Expect Breakeven For Iterum Therapeutics plc (NASDAQ:ITRM) Before Long simplywall.st

Iterum Nata – From The Infinite Light Review - Angry Metal Guy

Iterum Nata – From The Infinite Light Review Angry Metal Guy

Iterum Therapeutics Faces Shareholder Pushback on Key Proposals - TipRanks

Iterum Therapeutics Faces Shareholder Pushback on Key Proposals TipRanks

Iterum Therapeutics Faces Nasdaq Delisting Notice - TipRanks

Iterum Therapeutics Faces Nasdaq Delisting Notice TipRanks

Iterum reports positive results from Phase III trial of oral sulopenem - Clinical Trials Arena

Iterum reports positive results from Phase III trial of oral sulopenem Clinical Trials Arena

Iterum Therapeutics Commences Rights Offering - Stock Titan

Iterum Therapeutics Commences Rights Offering Stock Titan

Joe Dobbes returns to his roots with new Iterum Wines project - OregonLive.com

Joe Dobbes returns to his roots with new Iterum Wines project OregonLive.com

Iterum nabs speedy FDA antibiotic review, but follows in the footsteps of bankrupt biotechs - Fierce Biotech

Iterum nabs speedy FDA antibiotic review, but follows in the footsteps of bankrupt biotechs Fierce Biotech

Is Iterum Therapeutics plc (ITRM) A Good Stock To Buy Now? - Yahoo Finance

Is Iterum Therapeutics plc (ITRM) A Good Stock To Buy Now? Yahoo Finance

Iterum files for $92M IPO to bankroll phase 3 trials of ex-Pfizer antibiotic - Fierce Biotech

Iterum files for $92M IPO to bankroll phase 3 trials of ex-Pfizer antibiotic Fierce Biotech

Iterum bags $65M for phase 3 trial of ex-Pfizer antibiotic - Fierce Biotech

Iterum bags $65M for phase 3 trial of ex-Pfizer antibiotic Fierce Biotech

ITRM Stock Price and Chart — NASDAQ:ITRM - TradingView

ITRM Stock Price and Chart — NASDAQ:ITRM TradingView

Top Iterum Education Ab Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant